Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (EW) is a Healthcare stock trading at $87.24 (as of 2026-07-15), with a market capitalization of $50.23B and a trailing P/E of 36.9. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Edwards Lifesciences develops products and technologies for structural heart disease and for critical care and surgical monitoring. It supplies transcatheter solutions for valve replacement and repair (including mitral and tricuspid therapies), surgical structural heart products, and hemodynamic monitoring and hypotension prediction software for clinicians in hospitals.

Understand Edwards Lifesciences Corporation: how it makes money

Edwards Lifesciences makes transcatheter and surgical structural heart devices, including heart valve replacement and repair systems, and it also sells critical care and surgical monitoring products, with revenue coming from net sales of these medical technologies to healthcare providers and patients.

Edwards' profit engine is closely tied to procedural adoption and utilization of its transcatheter structural heart therapies, which show up in operating activity KPIs such as PASCAL/EVOC-related therapy cells and mitral and tricuspid patients treated, and are benchmarked against broader transcatheter valve adoption.

Business quality (Strong): Strong focus on structural heart valve replacement and repair plus monitoring, with operating outcomes and adoption captured through therapy and patient-treated metrics, but investor attention should stay on whether therapy volumes keep expanding.

Valuation: At 46× earnings, EW trades 44% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

Broad structural heart offering in valve therapies: Edwards provides transcatheter heart valve replacement and valve repair and replacement products, including systems such as PASCAL and Cardioband, for minimally invasive treatment of mitral and tricuspid valve diseases.
Revenue supported by high device and technology profitability: In the latest reported period, gross margin was 78.0% and operating margin was 29.0%, indicating strong profitability on its product and technology sales.

Bear case

Dependence on real-world procedural adoption: Because the company tracks adoption through cells and patients treated, slower growth in transcatheter mitral and tricuspid therapies could pressure future performance.
Benchmarking pressure across valve categories: Operating focus includes benchmarks such as Sapien-treated patients and aortic valve replacement study metrics, so category momentum and center adoption matter for continued traction.

Valuation — source: SEC EDGAR (first-party)
Price	$87.24
Market Cap	$50.23B
P/E Ratio	36.9
EV / EBITDA	26.1
Price / Book	4.86
Price / Sales	8.17
FCF Yield	3.3%
DCF Value (model)	$30.61
DCF Upside vs Price	-64.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$6.07B
Net Margin	17.7%
Revenue Growth (YoY)	11.5%
EPS Growth (YoY)	-73.6%
FCF Growth (YoY)	360.5%

Financial Health — source: SEC EDGAR
Altman Z-Score	11.68 (safe)
Piotroski F-Score	6/9 (moderate)

Valuation vs Sector & Industry
Stock P/E	36.9
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	30.2
vs Sector	75.7%
vs Industry	22.5%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($5.97B)
Institutional Holders Tracked	10
Congressional Trades (recent)	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Bernard J. Zovighian
Employees	15,800
Country	US
IPO Date	2000-03-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-07-15.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.